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Abstract
Background: Type 1 Diabetes Mellitus results from an autoimmune destruction of the pancreatic
beta cells, which produce insulin. The lack of insulin leads to chronic hyperglycemia and secondary
complications, such as cardiovascular disease. The currently approved clinical treatments for
diabetes mellitus often fail to achieve sustained and optimal glycemic control. Therefore, there is a
great interest in the development of surrogate beta cells as a treatment for type 1 diabetes.
Normally, pancreatic beta cells produce and secrete insulin only in response to increased blood
glucose levels. However in many cases, insulin secretion from non-beta cells engineered to produce
insulin occurs in a glucose-independent manner. In the present study we engineered liver cells to
produce and secrete insulin and insulin secretion can be stimulated via the nitric oxide pathway.
Results: Expression of either human insulin or the beta cell specific transcription factors PDX-1,
NeuroD1 and MafA in the Hepa1-6 cell line or primary liver cells via adenoviral gene transfer,
results in production and secretion of insulin. Although, the secretion of insulin is not significantly
increased in response to high glucose, treatment of these engineered liver cells with L-arginine
stimulates insulin secretion up to three-fold. This L-arginine-mediated insulin release is dependent
on the production of nitric oxide.
Conclusion: Liver cells can be engineered to produce insulin and insulin secretion can be induced
by treatment with L-arginine via the production of nitric oxide.
Background
Insulin is essential in maintaining normal blood glucose
levels and is produced and secreted by the beta cells of
pancreas in response to increased blood glucose levels.
Defects in insulin production and secretion, as observed
in type 1 diabetes due to autoimmune destruction of the
pancreatic beta cells, result in chronic hyperglycemia,
which is responsible for most of the secondary complica-
tions associated with diabetes. Besides insulin injections,
the only other option for treatment of type 1 diabetes is
islet transplantation. Because of the lack of insulin pro-
duction, gene therapy using surrogate beta cells is a poten-
tial approach in the treatment of Type 1 diabetes [1-3].
Delivery of insulin by gene therapy represents an attrac-
tive alternative to protein replacement therapy by poten-
tially providing a more convenient and cost-effective
delivery strategy.
Successful therapy for Type 1 diabetes requires that
mature insulin be produced and secreted from surrogate
beta-cells in a glucose-regulated manner. Liver appears to
be an excellent surrogate organ for production of insulin,
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because it contains a glucose sensing machinery that is
similar to pancreatic beta cells [4-7]. Liver and pancreatic
beta cells both express GLUT-2 and glucokinase [7,8].
Moreover, viral gene transfer into hepatocytes is very effi-
cient and the liver is also capable of mediating the produc-
tion and release of therapeutic proteins into the systemic
circulation. One major caveat of hepatic insulin produc-
tion via gene therapy is that hepatocytes lack a regulated
insulin secretory machinery that is present in pancreatic
beta cells. Several different viral and non-viral vectors are
available to target insulin expression to liver [9-11].
Several studies indicate that liver cells can be engineered
to secrete biologically active insulin [12-14]. Furthermore,
it has been demonstrated that introduction of the beta-
cell specific transcription factors PDX-1 and NeuroD1
into hepatocytes ameliorates streptozotocin-induced
hyperlgycemia in mice [15-17]. In a recent study, hepato-
cytes transfected with NeuroD1 and betacellulin, a β-cell
growth factor, have been shown to produce insulin and to
normalize blood glucose levels in streptozotocin-induced
diabetic mice [18].
Changes in blood glucose levels directly control insulin
secretion and also modulate the insulin-releasing effects
of other secretagogues in pancreatic beta cells [19]. In
addition to insulin secretion, increases in blood glucose
levels also regulate insulin gene transcription by modulat-
ing the function of three beta cell specific transcription
factors known as PDX-1, MafA and NeuroD1. Defects in
these transcription factors have been associated with
decreased insulin production and hyperglycemia [20,21].
In this study we demonstrate that the expression of
human insulin or the beta-cell specific transcription fac-
tors PDX-1, MafA and NeuroD1 in the Hepa1-6 liver cell
line or in primary liver cells using adenoviral gene trans-
fer, results in production and secretion of insulin. Further-
more, we show that insulin secretion from these
engineered liver cells is stimulated by treatment with L-
arginine via the nitric oxide pathway. L-arginine potenti-
ates insulin secretion also in other cell lines such as
fibroblasts and cervical carcinoma cells incubated with an
adenovirus containing the human insulin cDNA. This
suggests that L-arginine stimulates protein secretion in
various cell types via the synthesis of nitric oxide. The reg-
ulation of protein secretion by nitric oxide may be useful
in the engineering of surrogate beta cells for the treatment
of type 1 diabetes.
Results
Hepa1-6 liver cells transfected with an adenoviral vector 
containing human insulin are able to produce and secrete 
insulin
To test whether liver cells can be engineered to produce
and secrete insulin in a regulated manner, we have incu-
bated the Hepa1-6 liver cell line with an adenovirus
expressing human insulin. Liver cells incubated with the
human insulin adenovirus produced detectable amounts
of insulin compared to the GFP only control virus, as
demonstrated by immunostaining with an insulin anti-
body (Additional File 1). Next we quantified the amount
of insulin secreted and the glucose-dependency of insulin
secretion after treatment with 1 or 25 mM glucose using
an insulin ELISA kit. The total amount of insulin secreted
was about 60 µU/106 cells and the amount of insulin
secreted in response to high glucose was not significantly
higher than insulin secretion at 1 mM glucose (Fig. 1).
L-Arginine induces insulin secretion in the Hepa1-6 liver 
cell line expressing human insulin via the nitric oxide 
pathway
Since L-arginine acts as a potentiator of insulin secretion
in pancreatic beta cells, we tested the effect of L-arginine
Hepa1-6 cells expressing the human insulin gene produce and secrete insu inFigur 1
Hepa1-6 cells expressing the human insulin gene pro-
duce and secrete insulin. Comparison of insulin secretion 
from Hepa1-6 cells infected with human insulin or control 
adenovirus, after treatment with 1 or 25 mM glucose for 1 h. 
Total insulin secretion is expressed as µU/ml * 106 cells.
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on insulin release in Hepa1-6 liver cells expressing human
insulin. Treatment with 20 mM L-arginine for 1 h in the
presence of 1 mM glucose increased insulin secretion over
3-fold (Fig. 2A). L-arginine has been reported to act via the
nitric oxide pathway and therefore we determined
whether the production of nitric oxide (NO) was respon-
sible for the increase in insulin secretion in Hepa1-6 cells
expressing human insulin. For this purpose, we treated
the Hepa1-6 cells expressing human insulin or GFP as
control with 100 µM L-NNA, an inhibitor of nitric oxide
synthase (NOS) in the presence or absence of L-arginine
(Fig. 2A). Treatment with the general NOS inhibitor L-
NNA for 1 h abolished the L-arginine-induced insulin
secretion in Hepa1-6 cells expressing human insulin (Fig.
2A). Treatment with L-NNA also inhibited basal insulin
secretion, suggesting the idea that NO is responsible for
some of the observed basal secretion of insulin.
Next, we tested whether the NO donor sodium nitroprus-
side (SNP) can induce insulin secretion similar to L-
arginine. For this purpose, Hepa1-6 liver cells were treated
with 100 µM SNP in the presence of 1 mM glucose for 1
h. Like L-arginine, SNP was also able to enhance insulin
secretion (Fig. 2B), indicating that production of NO
stimulates insulin secretion. Both, basal and L-arginine
induced insulin secretion was dependent on the presence
of extracellular calcium (Additional File 2A). Hepa1-6
cells incubated with KRB buffer lacking calcium displayed
a 2-fold reduction in insulin secretion independent of the
presence of L-arginine (Additional File 2A). Furthermore,
inhibition of calcium channels using nifedipine abolished
both basal and L-arginine stimulated insulin release
(Additional File 2A).
Insulin secretion in pancreatic beta cells is mediated by
regulated exocytosis in which the insulin containing gran-
ules fuse with the plasma membrane [22,23]. However,
liver cells do not have a regulated exocytosis pathway and
secretion in liver cells occurs via the constitutive secretory
pathway. To test the effect of L-arginine on constitutive
secretion in liver cells, we have treated Hepa1-6 cells
expressing human insulin with brefeldin A (BFA), which
blocks the constitutive secretion pathway by inhibiting
the transport of proteins into the Golgi apparatus [24].
Treatment with brefeldin A blocked both basal and L-
arginine stimulated insulin secretion in Hepa1-6 cells
(Additional File 2B), but did not effect the secretion of
insulin from MIN6 insulinoma cells, which occurs via reg-
ulated exocytosis from insulin granules (Additional File
2C).
L-Arginine stimulates insulin secretion in various non-beta 
cell lines incubated with the human insulin adenovirus
To determine whether the stimulatory effect of L-arginine
on insulin secretion is specific to liver cells or not, we
incubated the following cell lines with the human insulin
adenovirus: HepG2 (human liver), NIH3T3 (mouse
fibroblast) and HeLa (human cervical carcinoma). All
three cell lines were able to produce and secrete insulin.
However insulin secretion was highest in the HepG2 cell
line and lowest in the HeLa cell line (Additional File 3).
Treatment with 20 mM L-arginine for 1 h stimulated insu-
lin secretion in every cell line tested to various degrees (Fig
3A–C). Addition of L-arginine enhanced insulin secretion
by about 2-fold in the human liver cell line HepG2 (Fig.
3A), while insulin secretion was less than 2-fold in the
fibroblast cell line NIH3T3 and human cervical carcinoma
(Fig. 3B &3C). In every cell line tested, stimulation of
insulin secretion by L-arginine was dependent on the pro-
duction of nitric oxide, since addition of L-NNA an inhib-
itor of nitric oxide synthase abolished L-arginine
mediated insulin secretion.
Hepa1-6 liver cells expressing beta-cell specific 
transcription factors produce and secrete insulin
It has been previously shown that the beta-cell specific
transcription factors such as PDX-1, NeuroD1 and MafA
are able to induce insulin gene transcription in non-beta
cells. Therefore, we introduced PDX-1, NeuroD1 and
L-arginine stimulates insulin secretion in Hepa1-6 cells expressing human insulin via the nitric oxide pathwayFigure 2
L-arginine stimulates insulin secretion in Hepa1-6 
cells expressing human insulin via the nitric oxide 
pathway. A. Hepa1-6 cells incubated with the human insulin 
adenovirus were transferred to 1 mM glucose with or with-
out 20 mM L-arginine in the presence or absence of the NOS 
inhibitor L-NNA (100 µM) for 1 h. The amount of secreted 
insulin in the medium was determined and is expressed as 
fold difference, where insulin secretion on 1 mM glucose was 
set as 1-fold. Values are expressed as means ± SD for n = 5 
in each group. B. Effect of NO donor sodium nitroprusside 
(SNP) on insulin secretion in Hepa1-6 cells. Insulin secretion 
in Hepa1-6 cells incubated with the human insulin adenovirus 
was measured after incubation of cells with 1 mM glucose, 
with or without 20 mM L-arginine or 100 µM SNP for 1 h (n 
= 3).
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MafA using adenoviral gene transfer into the Hepa1-6
liver cell line and determined their effects on insulin pro-
duction and secretion from liver cells. As demonstrated in
Fig. 4, expression of all three beta-cell transcription factors
in combination as well as individually induces insulin
production in Hepa1-6 cells compared to cells expressing
only GFP as control. Insulin secretion was highest in
Hepa1-6 cells expressing PDX-1 and lowest in Hepa1-6
cells expressing MafA (Fig. 5A). Insulin secretion in
Hepa1-6 cells expressing all three transcription factors at
the same time was increased about 1.7-fold by addition of
20 mM L-arginine (Fig. 5B). L-Arginine stimulated insulin
secretion was inhibited by addition of 100 µM L-NNA,
which inhibits NOS (Fig. 5B).
L-arginine induces insulin secretion in primary rat liver cells 
expressing human insulin
All of our initial experiments were carried out using the
hepatoma carcinoma cell line Hepa1-6. Thus, we next
confirmed the effects of L-arginine on insulin secretion in
primary rat liver cells expressing human insulin. For this
purpose, primary rat liver cells were cultured and incu-
bated with an adenovirus containing human insulin
(Additional File 4A). Insulin secretion from primary hepa-
tocytes was comparable to insulin secretion from the
Hepa1-6 cell line expressing human insulin and was
slightly increased on high glucose compared to low glu-
cose (Additional File 4B). As observed with the Hepa1-6
cell line, secretion of insulin was more than 3-fold higher
when primary rat liver cells expressing human insulin
were incubated with 1 mM glucose in the presence of 20
mM L-arginine (Fig. 6A). The L-arginine mediated
increase in insulin secretion was abolished after treatment
with 100 µM L-NNA (Fig. 6A), consistent with the idea
that L-arginine stimulates insulin secretion via the nitric
oxide pathway.
Primary rat liver cells expressing the beta-cell specific 
transcription factors PDX-1, NeuroD1 and MafA produce 
and secrete insulin
In addition to the human insulin adenovirus, we incu-
bated primary rat liver cells with a combination of PDX-1,
NeuroD1 and MafA adenoviruses. The expression of these
transcription factors in primary liver cells was confirmed
by western blotting (Additional File 5A). We found that
insulin secretion in primary rat liver cells expressing the
transcription factors was only 4% of that observed in pri-
mary hepatocytes expressing human insulin (Additional
File 5B). Insulin secretion was also slightly increased by
high glucose (Additional File 5B). Incubation of these
cells with 20 mM L-arginine in the presence of 1 mM glu-
cose increased insulin secretion by 2-fold (Fig. 6B). The
observed increase in insulin secretion was diminished
after addition of the NOS inhibitor L-NNA (Fig. 6B).
L-arginine stimulates insulin secretion in various cell lines incubated with the human insulin adenovirusFigure 3
L-arginine stimulates insulin secretion in various cell lines incubated with the human insulin adenovirus. A. 
HepG2, B. NIH 3T3, and C. HeLa cells incubated with the human insulin adenovirus were transferred to 1 mM glucose over-
night and washed with KRB buffer. After addition of 25 mM glucose or 1 mM glucose with or without 20 mM L-arginine and 
100 µM L-NNA, insulin release was measured in the medium and is expressed as fold-difference over insulin secretion at 1 mM 
glucose.
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Discussion
In this study, we have demonstrated that expression of
human insulin or beta cell specific transcription factors in
the Hepa1-6 liver cell line or primary rat hepatocytes
results in production and secretion of insulin. However,
the secretion of insulin from these engineered cells was
not very responsive to changes in glucose levels. Further-
more, we have expressed human insulin also in various
cell lines such as HepG2 (human hepatoma), NIH3T3
(mouse fibroblast) and HeLa (human cervical cancer)
cells. All of these cell lines were able to produce and
secrete insulin.
L-arginine has been found to stimulate insulin secretion
in pancreatic beta cells [25-27]. Therefore, we determined
the effect of L-arginine on insulin secretion from the engi-
neered Hepa1-6 cell line or primary hepatocytes and
found that L-arginine stimulates insulin secretion up to 3-
fold in these engineered tissues. The L-arginine mediated
enhancement of insulin secretion was via the production
of NO, since inhibition of nitric oxide synthase (NOS)
abolished this effect. Furthermore, treatment with sodium
nitroprusside, which is an NO donor stimulated insulin
secretion similar to L-arginine.
Insulin secretion from Hepa1-6 cells expressing human
insulin depends on the presence of calcium. Lack of cal-
cium or inhibition of the calcium channels with nifed-
ipine abolishes both basal and L-arginine stimulated
insulin secretion. Brefeldin A (BFA) is an agent that blocks
the transport of proinsulin to the trans-Golgi network, but
has no effect on insulin secretion via granule exocytosis
[24]. Addition of BFA to Hepa1-6 cells expressing human
insulin blocked the secretion of insulin, while it had no
effect on glucose-induced insulin secretion from the pan-
creatic beta cell line MIN6. This indicates that insulin
secretion from Hepa1-6 cells expressing human insulin is
due to constitutive secretion, while secretion of insulin in
pancreatic beta cells occurs via the regulated exocytotic
pathway as expected. Furthermore, L-arginine-mediated
insulin secretion was also inhibited by BFA, suggesting
that L-arginine stimulates insulin secretion via the nitric
oxide pathway by enhancing the constitutive protein
secretion pathway.
Hepa1-6 cells expressing PDX-1, NeuroD1 and MafA produce insulinFigure 4
Hepa1-6 cells expressing PDX-1, NeuroD1 and MafA produce insulin. Hepa1-6 cells incubated with PDX-1, 
NeuroD1, or MafA adenoviruses separately or with all three at the same time (PNM) were immunostained for mouse insulin 
using a specific antibody (red). Cell nuclei were stained with DAPI (blue). Infected cells were identified by green fluorescence of 
GFP.
NeuroD1
DAPI Anti-Insulin GFP Merge
PDX-1
PNM
MafA
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The exact mechanism(s) by which NO produced from L-
arginine stimulates insulin secretion from liver cells is not
known. Since liver cells were exposed to L-arginine only
for 1 h, the observed enhancement of insulin secretion is
unlikely due to transcriptional effects. There was no differ-
ence in insulin mRNA levels in cells treated with L-
arginine for 1 h compared to untreated cells (data not
shown). NO has been previously reported to stimulate
synaptic vesicle exocytosis. Synaptic proteins such as
SNAP 25, syntaxin and VAMP are known to be involved in
NO mediated secretion [28]. It has been reported that NO
is capable of S-nitrosylation of neuronal proteins includ-
ing SNAP-25 and NSF [29]. NO has been also shown to
associate with SNARE proteins, which play a main role in
the secretory pathway [30]. We propose that the produc-
tion of NO from L-arginine enhances secretion in liver by
either nitrosylation of secretory proteins such as SNAP-25
or by direct interaction of NO with the secretory pathway.
Conclusion
The presented data indicate that liver cells and other non-
beta cells can be engineered to produce and secrete insu-
lin. Although insulin secretion from these engineered cells
is not very responsive to changes in glucose levels, addi-
tion of L-arginine stimulates insulin secretion up to 3-fold
via the nitric oxide pathway. Stimulation of insulin secre-
tion from surrogate beta cells via the production of NO
could provide a potential therapy for the treatment of type
1 diabetes. Instead of glucose, engineered liver cells can be
induced to secrete insulin using nitric oxide precursors
such as nitroprusside. Since nitric oxide is very unstable,
insulin secretion stimulated by nitric oxide would be tran-
sient and may avoid hypoglycemia as observed by consti-
tutive secretion of insulin from engineered cells. Further
studies will investigate the molecular basis of stimulation
of insulin secretion by L-arginine in surrogate β cells,
which will be a useful step in the development of insulin-
replacement therapies of diabetes. Future experiments
will also determine whether L-arginine can stimulate insu-
lin secretion and thereby correct hyperglycemia in dia-
betic animals expressing insulin in liver.
Methods
Chemicals and reagents
Materials used are Waymouth's MB 752/1 medium (Invit-
rogen), Matrigel (BD Biosciences), insulin ultrasensitive
ELISA kit (Mercodia); L-NNA (N-G-nitro-l-arginine, a
nitric oxide synthase inhibitor) (Sigma), and Brefeldin A
(Chemicon). All of the other chemicals were from Sigma
Chemicals unless otherwise noted.
Construction of the adenoviruses expressing human 
insulin, PDX-1, NeuroD1 and MafA
Recombinant adenoviruses expressing human insulin
[31], PDX-1, NeuroD1 and MafA were prepared using the
pAdEasy system [32,33] under the control of human
cytomegalovirus (CMV) promoter. As a negative control,
we used the empty adenoviral vector pAdTrackCMV
Insulin secretion in Hepa1-6 cells expressing the beta-cell spec fic transcription factors is increas d by treatment with L-arginineFigure 5
Insulin secretion in Hepa1-6 cells expressing the 
beta-cell specific transcription factors is increased by 
treatment with L-arginine. A. Insulin secretion in Hepa1-
6 cells expressing PDX-1, NeuroD1 or MafA individually or 
in combination was determined using a mouse insulin ELISA 
kit. After incubation with the corresponding adenoviruses, 
the cells were incubated first over night with 1 mM glucose 
and then transferred to KRB buffer containing 25 mM glu-
cose. Total insulin secretion is expressed as µU/ml * 106 
cells. B. Hepa1-6 cells expressing all three transcription fac-
tors, PDX-1, NeuroD1 and MafA were incubated for 1 h in 
KRB buffer containing 1 mM glucose with or without 20 mM 
L-arginine and 100 µM L-NNA. The amount insulin in the 
media was quantified by an insulin ELISA assay. The data are 
averages of five (n = 5) independent experiments.
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Treatment with L-arginine induces insulin secretion in pri-mary hepatocytes expressing human insulin o  the beta-cell sp cific transcription factorsFigure 6
Treatment with L-arginine induces insulin secretion 
in primary hepatocytes expressing human insulin or 
the beta-cell specific transcription factors. Primary rat 
hepatocytes were incubated either with the human insulin 
(panel A) or a combination of PDX-1, NeuroD1 and MafA 
adenoviruses (panel B). After incubation on 1 mM glucose for 
about 16 h, the cells were transferred to KRB buffer contain-
ing 1 mM glucose in the presence or absence of 20 mM L-
arginine and 100 µM L-NNA. Insulin secretion in the media 
was measured in three independent experiments and is 
expressed as fold difference of insulin secretion of 1 mM glu-
cose incubated cells.
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expressing GFP. After subcloning of human insulin, PDX-
1, NeuroD1 and MafA into the pAdTrackCMV vector, the
vector was linearized and co-transformed into the bacte-
rial strain BJ5183 with the adenoviral backbone plasmid
pAdEasy-1. The recombinant adenoviral vectors were
obtained by homologous recombination of pAdTrack-
CMV with pAdEasy-1 and the resultant plasmids were
then re-transformed and amplified in DH5α cells. The
obtained plasmids were linearized with Pac I and then
transfected into the adenovirus packaging cell line HEK
293 by electroporation at 400 V and 500-µF using the
GenePulser II electroporator (Biorad). The electropora-
tion was carried out using a cell concentration of 2 × 106
cells per cuvette in DMEM (Cellgro) without serum. The
cells were harvested fourteen to fifteen days after transfec-
tion, when 70–80% of the cells expressed Green Fluores-
cent Protein (GFP). The negative control adenovirus
expressing only GFP was prepared in the same manner.
After lysis of the HEK293 cells by freezing and thawing,
the cell supernatant containing the viruses was collected
and used for further amplification of the recombinant
adenoviruses. The efficiency of adenoviral infection was
determined by the ratio of cells expressing GFP.
Isolation and culturing of adult rat hepatocytes
Animals were kept under standard conditions in the ani-
mal facility and had free access to food and water. This
study was approved by the Institutional Animal Care and
Use Committee (IACUC), University of Kentucky. The tis-
sue culture dishes were treated with Matrigel (6.3 mg/ml)
as described previously [34]. Hepatocytes were isolated
from male Sprague-Dawley rats (180–200 g) (Harlan, Inc.
Indianapolis, IN). For the isolation of primary hepato-
cytes, rats were anesthetized by intraperitoneal injection
of sodium pentobarbitone. After in situ collagenase per-
fusion, the cells (1 × 106/plate; viability > 80%) were
plated in 3 ml of Waymouth's medium. Cultures were
maintained for two days at 37°C in a 5% CO2 atmosphere
and the medium was replaced every 24 h, starting 3 h after
plating. Primary hepatocytes were incubated with adeno-
viruses expressing human insulin, PDX-1, NeuroD1 and
MafA, and GFP as control.
Cell culture conditions
Hepa1-6 cells (mouse hepatocyte cell line) were cultured
in a humidified atmosphere at 37°C with 5% CO2, and
grown in DMEM (Dulbecco's modified Eagle's medium)
containing 10% (v/v) heat-inactivated fetal bovine serum,
25 mM glucose, 100 U/ml penicillin, and 100 mg/ml
streptomycin [35].
Insulin-ELISA assay
To quantify the amount of insulin secreted, hepatocytes
were grown on a 6-well dish (about 1 × 106 cells) and
incubated over night with various adenoviruses in DMEM
with 10% FBS. After this incubation period, the cells were
washed twice with 1×PBS and incubated for 14–16 h with
1 mM glucose without FBS. After washing the cells three
times with KRB buffer (119 mM NaCl, 4.7 mM KCl, 2.5
mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM
NaHCO3, 10 mM Hepes, pH 7.4, and 0.1 g BSA), the cells
were incubated in 1 ml pre-warmed KRB buffer contain-
ing 1 mM or 25 mM glucose with or without 20 mM L-
arginine in the absence or presence of various compounds
for 1 h at 37°C. The cell culture media (total of 1 ml) was
collected and used to measure the levels of insulin
released with an insulin ELISA kit (Mercodia). The
amount of secreted insulin is given in µU per 1 × 106 cells.
Fold stimulation refers to insulin secretion after various
treatments compared to insulin secretion in 1 mM glucose
treated cells, which was set as 1-fold. Values are expressed
as means ± SD of data obtained from three to five inde-
pendent experiments (n = 3 to 5) in duplicates.
Western blotting
Protein extracts from hepatocytes infected with PDX-1,
NeuroD1, MafA and GFP adenoviruses were blotted with
PDX-1 (a gift from Dr. Chris Wright, Vanderbilt Univer-
sity), NeuroD1 (Santa Cruz Biotechnology), MafA (Calbi-
ochem) and GFP (Clontech Laboratories) antibodies.
Proteins were visualized by enhanced chemiluminescence
(ECL) western blotting detection kit (Amersham Bio-
science).
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